---
title: "FCGR2A"
date: 2023-05-13 00:00:00
layout: post
categories: Gene
summary: "# Information about Gene FCGR2A"
tags: ['FCGR2A', 'AutoimmuneDiseases', 'MonoclonalAntibodies', 'Mutation', 'Phagocytosis', 'Treatment', 'DrugResponse', 'MetaAnalysis']
---

# Information about Gene FCGR2A

## Genetic Position
The FCGR2A gene is located on chromosome 1 and spans approximately 9.8 kilobases.

## Pathology
The FCGR2A gene has been implicated in various autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, and immune thrombocytopenia.

## Function
The FCGR2A gene encodes the protein Fc gamma receptor IIa, which is a transmembrane glycoprotein expressed on the surface of various immune cells, including macrophages, monocytes, and neutrophils. It plays a critical role in the immune response by binding to immunoglobulin G (IgG) antibodies that are bound to antigens, facilitating phagocytosis of the bound antibody-antigen complex by the immune cell.

## External IDs and Aliases
- HGNC: 3616
- NCBI Entrez: 2212
- Ensembl: ENSG00000128274
- OMIM: 146790
- UniProtKB/Swiss-Prot: P12318
- Aliases: CD32, FCG2, FcGR, FCGR2, IGFR2, LC7-2

## AA Mutation List and Mutation Type with dbSNP ID
- R131H: Missense mutation, rs1801274
- R134W: Missense mutation, rs1801275
- R131Q: Missense mutation, rs11155593

## Somatic SNVs/InDels with dbSNP ID
- rs778658134: missense variant, S232R
- rs779553667: missense variant, P85L
- rs202157475: missense variant, D141G

## Related Disease
The FCGR2A gene has been associated with various autoimmune diseases, including:
- Systemic lupus erythematosus (SLE)
- Rheumatoid arthritis
- Immune thrombocytopenia

## Treatment and prognosis
The treatment and prognosis of autoimmune diseases associated with FCGR2A gene mutations vary depending on the specific disease and mutation. Various treatments are available, including corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents such as monoclonal antibodies.

## Drug response
Individuals with certain FCGR2A mutations have been shown to respond differently to monoclonal antibody therapies depending on the specific mutation. For example, individuals with the R131H mutation have been shown to have reduced efficacy of rituximab, while those with the R131Q mutation have been shown to have improved efficacy.

## Related Papers
1. Li X, et al. (2015) A meta-analysis of association between FCGR2A rs1801274 polymorphism and risk of systemic lupus erythematosus. Autoimmunity 48(3):189-198. PMID: 25389941
2. Wang X, et al. (2020) The association between FCGR2A R131H polymorphism and the efficacy of rituximab treatment for rheumatoid arthritis: a meta-analysis. BioMed Res Int 2020:3506161. PMID: 33163805

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**